Pioneering Myeloprotective Drugs for Cancer patients
Zymeron, a preclinical pharmaceutical startup, is dedicated to developing myeloprotective drugs that shield bone marrow from the toxic effects of chemotherapy. MyeloShield is transforming the clinical management of myelosuppression and cytopenia from reactive to preventive with the goal to improve the quality of life and medication adherence for chemotherapy patients.
Our Technologies
Our innovators developed drug delivery and formulation technologies to bridge gaps in pharmaceutical sciences that are manifested by multiple unmet clinical needs.
Bone Marrow Drug Delivery Platform – Our proprietary peptide drug conjugate (PDC) demonstrated its advantages and benefits in delivering a cytoprotective molecule to protect hematopoietic stem and progenitor cells from chemotherapy or radiation induced myelotoxicity.
Reformulate Poorly Soluble Drugs to Injectables – Converting insoluble or poorly soluble small molecule drugs to highly soluble non-covalent molecular variants is a requirement to repurpose these oral drugs for use as emergency medicine (hemorrhage shock, sepsis).
Our Partners
We have an extended list of partners in academia, industry, government, and non-profit organizations. We work closely with numerous government agencies including the Department of Defense and the Department of Health and Human Services to develop innovative products to meet the nation’s health and defense needs. We commercialize advanced materials and health-related technologies and bring them to market in partnership with commercial entities.